Core Scientific, Inc.

DB:7ZD Stock Report

Market Cap: €4.8b

Core Scientific Valuation

Is 7ZD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 7ZD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 7ZD's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 7ZD's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7ZD?

Key metric: As 7ZD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 7ZD. This is calculated by dividing 7ZD's market cap by their current revenue.
What is 7ZD's PS Ratio?
PS Ratio17.2x
SalesUS$334.18m
Market CapUS$5.75b

Price to Sales Ratio vs Peers

How does 7ZD's PS Ratio compare to its peers?

The above table shows the PS ratio for 7ZD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.5x
NEM Nemetschek
7.1x12.43%€8.2b
AOF ATOSS Software
7.7x12.17%€1.4b
MUM Mensch und Maschine Software
3x9.24%€706.8m
NB2 Northern Data
4x33.13%€808.2m
7ZD Core Scientific
17.2x31.36%€5.8b

Price-To-Sales vs Peers: 7ZD is expensive based on its Price-To-Sales Ratio (17.2x) compared to the peer average (5.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 7ZD's PS Ratio compare vs other companies in the DE Software Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
CSH CENIT
0.3x3.00%US$69.19m
LSX LS telcom
0.5x2.07%US$25.81m
ISHA INTERSHOP Communications
0.6x5.82%US$22.55m
CLIQ Cliq Digital
0.06x-27.91%US$11.51m
7ZD 17.2xIndustry Avg. 1.9xNo. of Companies10PS02.44.87.29.612+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 7ZD is expensive based on its Price-To-Sales Ratio (17.2x) compared to the German Software industry average (1.9x).

Price to Sales Ratio vs Fair Ratio

What is 7ZD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7ZD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.2x
Fair PS Ratio4.6x

Price-To-Sales vs Fair Ratio: 7ZD is expensive based on its Price-To-Sales Ratio (17.2x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7ZD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€15.50
€21.85
+40.97%
16.00%€28.54€14.27n/a15
Feb ’27€15.10
€22.65
+49.98%
19.56%€33.67€14.31n/a16
Jan ’27€12.70
€22.86
+80.01%
21.28%€34.16€14.52n/a15
Dec ’26€14.35
€23.62
+64.61%
19.50%€34.46€14.64n/a13
Nov ’26€18.50
€22.90
+23.76%
23.56%€34.70€14.75n/a14
Oct ’26€15.25
€16.51
+8.25%
12.40%€19.65€14.53n/a11
Sep ’26€12.15
€16.41
+35.07%
14.09%€19.82€12.93n/a11
Aug ’26€10.85
€15.93
+46.85%
13.74%€19.86€12.95n/a10
Jul ’26€14.55
€15.36
+5.58%
13.33%€19.53€12.74n/a16
Jun ’26€9.34
€15.83
+69.45%
13.72%€20.26€13.21n/a16
May ’26n/a
€16.39
0%
14.06%€21.26€12.40n/a15
Apr ’26n/a
€18.01
0%
11.62%€22.25€15.76n/a15
Mar ’26n/a
€18.87
0%
11.78%€23.07€16.34n/a15
Feb ’26n/a
€19.86
0%
15.19%€24.99€16.34€15.1015
Jan ’26n/a
€19.61
0%
15.77%€25.10€16.41€12.7013
Dec ’25n/a
€19.02
0%
15.47%€24.82€16.23€14.3513
Nov ’25n/a
€15.94
0%
13.18%€21.15€13.79€18.5012
Oct ’25n/a
€14.62
0%
11.15%€17.97€11.68€15.2511
Sep ’25n/a
€14.92
0%
13.27%€18.30€11.89€12.158
Aug ’25n/a
€14.88
0%
12.92%€18.39€11.95€10.858
Jul ’25n/a
€13.39
0%
17.40%€15.88€10.28€14.553
Jun ’25n/a
€6.64
0%
21.57%€7.87€4.63€9.343
May ’25n/a
€6.17
0%
25.93%€7.77€4.57n/a2
Apr ’25n/a
€6.17
0%
25.93%€7.77€4.57n/a2
Mar ’25n/a
€6.22
0%
25.93%€7.84€4.61n/a2
Feb ’25n/a
€6.25
0%
25.93%€7.87€4.63n/a2
€21.75
Fair Value
28.7% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/10 09:39
End of Day Share Price 2026/02/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Core Scientific, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ramsey El-AssalBarclays
Gautam ChhuganiBernstein
Nicholas GilesB. Riley Securities, Inc.